CANNAPHARMARX, INC.

CPMD ·Healthcare, Drug Manufacturers - General
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2010 FY2009
Revenue
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development
SG&A Expense $91.4K $93.6K
Operating Income $585.6K $113.7K
Operating Margin
Interest Expense
Pretax Income $575.4K $108.9K
Income Tax Expense
Net Income $575.4K $108.9K
Net Margin
EPS (Basic) $0.04
EPS (Diluted) $0.04
Shares Outstanding (Basic) 14.3M 14.2M
Shares Outstanding (Diluted) 14.3M 14.2M
Dividends Per Share
← Newer Page 3 of 3 Older →